| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/16/2009 | EP2100615A1 Cancer therapy |
| 09/16/2009 | EP2100612A2 Semi-solid mucoadhesive formulations |
| 09/16/2009 | EP2100611A1 Glucose metabolism ameliorating agent |
| 09/16/2009 | EP2100610A1 Pharmaceutical composition containing low-substituted hydroxypropylcellulose |
| 09/16/2009 | EP2100609A1 Solid medicinal preparation containing mannitol or lactose |
| 09/16/2009 | EP2100608A1 Method for producing solid preparation |
| 09/16/2009 | EP2100607A1 Pharmaceutical composition having improved storage stability |
| 09/16/2009 | EP2100606A1 Film-coated preparation having improved stability |
| 09/16/2009 | EP2100605A1 Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer |
| 09/16/2009 | EP2100604A1 Medium chain dicarboxylic acids and their derivates and metabolic disorders |
| 09/16/2009 | EP2100603A1 Use of malachite green in the form of drug for treating malignant neoplasms |
| 09/16/2009 | EP2100602A1 Method and compositions suitable for treatment of wounds |
| 09/16/2009 | EP2100601A2 Topical pharmaceutical foam composition |
| 09/16/2009 | EP2100600A1 Extended release oral dosage composition |
| 09/16/2009 | EP2100599A1 Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| 09/16/2009 | EP2100598A1 Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| 09/16/2009 | EP2100596A2 Injectable liquid paracetamol formulation |
| 09/16/2009 | EP2100588A1 Prophylactic or therapeutic agent for alopecia |
| 09/16/2009 | EP2100139A2 Biologically active compositions, methods for producing the same and biological applications |
| 09/16/2009 | EP2099814A1 Substituted estratrien derivatives as 17beta hsd inhibitors |
| 09/16/2009 | EP2099813A2 Alpha-galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them |
| 09/16/2009 | EP2099806A1 Spiropiperidine derivatives as nk3 antagonists |
| 09/16/2009 | EP2099805A2 Novel aminothienopyridinone derivatives processes for preparing them and pharmaceutical compositions thereof |
| 09/16/2009 | EP2099804A1 Compounds for the treatment of hepatitis c |
| 09/16/2009 | EP2099803A1 Heterobicyclic matrix metalloprotease inhibitors |
| 09/16/2009 | EP2099800A1 7-substituted purine derivatives for immunosuppression |
| 09/16/2009 | EP2099799A1 Spiro-piperidine derivatives |
| 09/16/2009 | EP2099798A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases |
| 09/16/2009 | EP2099797A2 Compounds and compositions as protein kinase inhibitors |
| 09/16/2009 | EP2099796A1 Aza-indolyl compounds and methods of use |
| 09/16/2009 | EP2099795A2 Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands |
| 09/16/2009 | EP2099793A1 Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| 09/16/2009 | EP2099792A1 Heterotricyclic metalloprotease inhibitors |
| 09/16/2009 | EP2099791A1 Thienyl-containing glycopyranosyl derivatives as antidiabetics |
| 09/16/2009 | EP2099789A1 Inhibitors of hiv replication |
| 09/16/2009 | EP2099788A1 Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof |
| 09/16/2009 | EP2099787A1 Aminopyrimidines useful as inhibitors of protein kinases |
| 09/16/2009 | EP2099786A1 Process for preparing a crystalline form of candesartan cilexetil |
| 09/16/2009 | EP2099784A2 1,5-diphenyl-3-pyridinylamino-1,5-dihydrioyrrolidin-2-ones as cb1 receptor modulators |
| 09/16/2009 | EP2099783A1 Bicyclic lactam factor viia inhibitors useful as anticoagulants |
| 09/16/2009 | EP2099782A2 Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd) |
| 09/16/2009 | EP2099781A1 Substituted 4-amino-3,5-dicyano-2-thiopyridines and use thereof |
| 09/16/2009 | EP2099780A1 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders |
| 09/16/2009 | EP2099779A1 Crystalline forms of aryl-substituted pyrazole-amide compounds |
| 09/16/2009 | EP2099777A1 Urea glucokinase activators |
| 09/16/2009 | EP2099776A1 Chelating agent |
| 09/16/2009 | EP2099775A2 Polymorphic forms of deferasirox (icl670a) |
| 09/16/2009 | EP2099774A1 Inhibitors of kinase activity |
| 09/16/2009 | EP2099771A1 Pyrimidine kinase inhibitors |
| 09/16/2009 | EP2099770A2 Pyridazinones and furan-containing compounds |
| 09/16/2009 | EP2099768A2 Agonists of the sphingosine-1-phosphate receptor |
| 09/16/2009 | EP2099767A1 Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof |
| 09/16/2009 | EP2099766A1 Pyrazole derivatives as non-steroidal glucocorticoid receptor ligands |
| 09/16/2009 | EP2099765A2 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives as antitumor agents |
| 09/16/2009 | EP2099763A1 2-aminoquinolines as 5-ht(5a) receptor antagonists |
| 09/16/2009 | EP2099762A1 Antibacterial quinoline derivatives |
| 09/16/2009 | EP2099761A2 Antibacterial quinoline derivatives |
| 09/16/2009 | EP2099760A1 Antibacterial quinoline derivatives |
| 09/16/2009 | EP2099759A1 Antibacterial quinoline derivatives |
| 09/16/2009 | EP2099758A1 Antibacterial quinoline derivatives |
| 09/16/2009 | EP2099757A2 Sulfoximines as kinase inhibitors |
| 09/16/2009 | EP2099756A1 N-hydroxyacrylamide compounds |
| 09/16/2009 | EP2099754A1 Ion channel modulators |
| 09/16/2009 | EP2099753A2 Heteroarylacrylamides and their use as pharmaceuticals |
| 09/16/2009 | EP2099752A1 Phenylamino-substituted piperidine compounds, their preparation and use as medicaments |
| 09/16/2009 | EP2099750A1 New crystalline forms |
| 09/16/2009 | EP2099503A1 Burn bandage |
| 09/16/2009 | EP2099492A2 Duloxetine composition |
| 09/16/2009 | EP2099490A1 New drug for inhibiting, preventing or treatment of rheumatoid arthritis |
| 09/16/2009 | EP2099478A2 Means and method for raising improved immune response |
| 09/16/2009 | EP2099476A1 Methods of treating alzheimer's disease |
| 09/16/2009 | EP2099473A2 Potentiation of erythropoietin (epo) action by membrane steroid receptor agonists |
| 09/16/2009 | EP2099469A2 Radiation protection and treatment for exposure to gamma-radiation |
| 09/16/2009 | EP2099468A2 Methods of use of trk receptor modulators |
| 09/16/2009 | EP2099464A2 Local administration of gallium compositions to treat pain |
| 09/16/2009 | EP2099462A1 Pharmaceutical preparation for the treatment of inflammatory diseases of the urogenital tract |
| 09/16/2009 | EP2099461A2 Lna nucleoside phosphoramidates |
| 09/16/2009 | EP2099460A2 6-alkoxyalkyl estradiol derivatives and methods of use |
| 09/16/2009 | EP2099459A1 Compounds and uses thereof |
| 09/16/2009 | EP2099458A2 Compounds and methods for enzyme-mediated tumor imaging and therapy |
| 09/16/2009 | EP2099457A2 Cytoskeletal active rho kinase inhibitor compounds, composition and use |
| 09/16/2009 | EP2099456A2 N-oxides of 4,5-epoxy-morphinanium analogs |
| 09/16/2009 | EP2099455A1 Methods and compositions for repelling arthropods |
| 09/16/2009 | EP2099454A2 Aminopyrrolidines as chemokine receptor antagonists |
| 09/16/2009 | EP2099453A2 Combination therapy of substituted oxazolidinones |
| 09/16/2009 | EP2099452A2 Tricarbonyl complexes with tridentate chelators for myocardium imaging |
| 09/16/2009 | EP2099451A2 Combination of an hdac inhibitor and an antimetabolite |
| 09/16/2009 | EP2099450A2 Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| 09/16/2009 | EP2099449A1 Pharmaceutical composition for the treatment and prevention of diseases involving impotence |
| 09/16/2009 | EP2099448A1 Pharmaceutical composition for treatment and prevention of restenosis |
| 09/16/2009 | EP2099447A1 Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| 09/16/2009 | EP2099446A1 Method of treatment for inflammatory bowel disease |
| 09/16/2009 | EP2099445A2 P53 activating benzoyl urea and benzoyl thiourea compounds |
| 09/16/2009 | EP2099444A1 Use of d-serine derivatives for the treatment of anxiety disorders |
| 09/16/2009 | EP2099443A1 Combination of er + ligands and histone deacetylase inhibitors for the treatment of cancer |
| 09/16/2009 | EP2099442A1 Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| 09/16/2009 | EP2099441A1 Metal delivery agents and therapeutic uses of the same |
| 09/16/2009 | EP2099440A1 Method for screening anti-cancer compounds inhibiting function of tm4sf5 and anti-cancer composition containing chalcone compounds |
| 09/16/2009 | EP2099439A2 Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
| 09/16/2009 | EP2099438A2 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |